Colorectal carcinoma (CRC) · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | None |
| ID | IND-CRC-METASTATIC-3L-RECHALLENGE-EGFRI |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L pathway for ctDNA-guided anti-EGFR rechallenge in RAS-WT mCRC. Requires ctDNA infrastructure (Guardant 360, FoundationOne Liquid CDx). Missing entity flag: dedicated REG-CETUXIMAB-RECHALLENGE — author in PROD-2.
Used By
No reverse references found in the YAML corpus.